A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma
PHASE2CompletedINTERVENTIONAL
Timeline
Start Date
March 31, 2001
Study Completion Date
December 31, 2004
Conditions
Multiple Myeloma
Interventions
DRUG
Pegylated Interferon
DRUG
Interferon-alpha2a
Trial Locations (1)
SM2 5PT
Royal Marsden NHS trust, Sutton
All Listed Sponsors
lead
Royal Marsden NHS Foundation Trust
OTHER
NCT00323505 - A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma | Biotech Hunter | Biotech Hunter